Skip to main content
Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001+irinotecan vs. regorafenib plus irinotecan in third/fourth-line colorectal cancer. Reid, T. R., Abrouk, N., Oronsky, B., Caroen, S., Fisher, G. A. LIPPINCOTT WILLIAMS & WILKINS. 2023: 97

View details for Web of Science ID 001093994600203